SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2023 Biotech Charity Contest
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: technetium who wrote (59)5/3/2023 5:41:44 PM
From: Aloner  Read Replies (1) of 233
 
Magenta Therapeutics Inc (NASDAQ: MGTA) and privately-held Dianthus Therapeutics Inc have announced to merge in an all-stock transaction.

The combined company will focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, currently in Phase 1 trial.

Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics Inc and trade on the Nasdaq under the ticker symbol DNTH.

Magenta's stockholders will own about 21.3% of the combined company.

Dianthus has secured a $70 million private investment from a syndicate of healthcare investors supporting the merger.

With the cash expected from both companies and the proceeds of the concurrent private financing, the combined company is expected to have approximately $180 million of cash sufficient to fund operations into mid-2026.

In January, following a patient death, Magenta Therapeutics paused the Phase 1/2 dose-escalation trial of its acute myeloid leukemia (AML) therapy.

In February, the company halted further program development and started looking for strategic alternatives.

Soon after, Magenta Therapeutics implemented a reduction of the company's workforce by up to 56 positions or approximately 84%.

Cash is expected to fund the lead program DNTH103 through multiple clinical data catalysts, including Phase 1 in healthy volunteers and Phase 2 trials in generalized Myasthenia Gravis and other indications.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News